Issue 10, 2023

Transferrin receptor 1 targeted nanomedicine for brain tumor therapy

Abstract

Achieving effective drug delivery to traverse the blood–brain barrier (BBB) and target tumor cells remains the greatest challenge for brain tumor therapy. Importantly, the overexpressed membrane receptors on the brain endothelial cells, especially transferrin receptor 1 (TfR1), which mediate their ligands/antibodies to overcome the BBB by transcytosis, have been emerging as promising targets for brain tumor therapy. By employing ligands (e.g., transferrin, H-ferritin), antibodies or targeting peptides of TfR1 or aptamers, various functional nano-formulations have been developed in the last decade. These agents showed great potential for the treatment of brain diseases due to their ideal size, high loading capacity, controlled drug release and suitable pharmacokinetics. Herein, we summarize the latest advances on TfR1-targeted nanomedicine for brain tumor therapy. Moreover, we also discuss the strategies of improving stability, targeting ability and accumulation of nano-formulations in brain tumors for better outcomes. In this review, we hope to provide inspiration for the rational design of TfR1-targeted nanomedicine against brain tumors.

Graphical abstract: Transferrin receptor 1 targeted nanomedicine for brain tumor therapy

Article information

Article type
Review Article
Submitted
28 dek 2022
Accepted
11 fev 2023
First published
13 fev 2023

Biomater. Sci., 2023,11, 3394-3413

Transferrin receptor 1 targeted nanomedicine for brain tumor therapy

J. Li, Z. Zhang, B. Zhang, X. Yan and K. Fan, Biomater. Sci., 2023, 11, 3394 DOI: 10.1039/D2BM02152H

To request permission to reproduce material from this article, please go to the Copyright Clearance Center request page.

If you are an author contributing to an RSC publication, you do not need to request permission provided correct acknowledgement is given.

If you are the author of this article, you do not need to request permission to reproduce figures and diagrams provided correct acknowledgement is given. If you want to reproduce the whole article in a third-party publication (excluding your thesis/dissertation for which permission is not required) please go to the Copyright Clearance Center request page.

Read more about how to correctly acknowledge RSC content.

Social activity

Spotlight

Advertisements